Appendicular Lean Mass Index (ALMI): The DEXA Scan Number That Predicts How Well You'll Age

Appendicular Lean Mass Index (ALMI) measures the muscle in your arms and legs scaled to your height. Of all the numbers on a whole-body DEXA scan report, it is the most clinically validated predictor of sarcopenia, frailty, disability, and all-cause mortality. If you have ever had a DEXA scan and ignored the ALMI line, you have missed the single most important data point on the page.

Find a DEXASCAN.com clinic near you →

What Is Appendicular Lean Mass Index (ALMI)?

Appendicular Lean Mass Index, or ALMI, is the total lean soft tissue mass in your arms and legs divided by your height in meters squared. It is reported in kilograms per square meter (kg/m²), the same units as Body Mass Index (BMI), but the comparison ends there.

The formula is straightforward:

ALMI = (Lean mass in arms + Lean mass in legs) ÷ Height² (m²)

The "appendicular" part is intentional. Your limb muscles are the ones you actively use to move, lift, climb stairs, stand up from a chair, and catch yourself when you stumble. They are also the first muscles to atrophy with aging, illness, immobilization, and aggressive weight loss — including weight loss on GLP-1 medications. Trunk and organ lean tissue is included in total lean mass, but it does not respond to training and disuse the same way limb muscle does. That is why the major sarcopenia consensus groups — the European Working Group on Sarcopenia in Older People (EWGSOP2), the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project, and the Asian Working Group for Sarcopenia (AWGS) — all built their diagnostic criteria around appendicular lean mass, not total lean mass.¹²³

When you get a whole-body DEXA scan at a DEXASCAN.com clinic, ALMI is calculated for you automatically. It belongs in the same conversation as your visceral fat, body fat percentage, and bone density — arguably ahead of them.

How ALMI Is Calculated From a DEXA Scan

A dual-energy X-ray absorptiometry (DEXA) scan passes two low-dose X-ray energies through the body. Because fat, lean soft tissue, and bone attenuate those energies differently, the scanner can separate your body into three distinct compartments region by region: head, trunk, arms, legs, and pelvis.

The scanner sums lean soft tissue in the left arm, right arm, left leg, and right leg to produce Appendicular Lean Mass (ALM) in kilograms. Dividing ALM by height squared yields ALMI.

A typical young, healthy reference range from recent DEXA reference data using a Hologic system looks like this:

These values come from a 2025 reference dataset of 1,111 healthy Polish adults scanned on Hologic Horizon DEXA — the same family of clinical scanners used in many of the DEXASCAN.com network.⁴

Two things make DEXA the right tool for this measurement:

1. DEXA is the practical gold standard for ALM. Magnetic resonance imaging (MRI) is the theoretical gold standard for true skeletal muscle, but the EWGSOP2 consensus explicitly recommends DEXA for routine clinical and research use because MRI and CT are slower, costlier, and impractical for whole-body screening.¹⁵
2. DEXA is region-specific. Bioelectrical impedance (BIA) scales — including most consumer "smart scales" — estimate total body fat-free mass using equations, not direct regional measurement. Multiple validation studies show BIA can produce ALM values significantly lower than DEXA on the same individual, with prevalence of low muscle mass shifting by more than 10 percentage points depending on the device used.³

If you are serious about tracking muscle, the measurement has to be regional, direct, and reproducible. That is exactly what a DEXA scan at a DEXASCAN.com network clinic delivers.

ALMI vs. BMI vs. FFMI: Why Most People Are Tracking the Wrong Number

BMI is weight divided by height squared. It does not distinguish between fat and muscle. A 200-pound powerlifter and a 200-pound sedentary office worker of the same height have the same BMI and radically different bodies. This is well understood and is exactly why BMI fails as a health metric for active adults and for anyone over 60.

FFMI (Fat-Free Mass Index) lumps together everything that is not fat: limb muscle, trunk muscle, organs, and bone. It is a "whole-body muscularity score," but it is heavily influenced by torso and organ mass, which do not respond meaningfully to training.

ALMI isolates the muscle that actually moves you. That is why it correlates with:

• Falls and fractures in older adults
• Mobility impairment (slow gait speed)
• All-cause mortality in middle-aged and older populations
• Cancer-specific mortality
• Cardiovascular mortality
• Bone mineral density

A 2025 NHANES analysis of nearly 47,000 U.S. adults found that higher ALM was associated with lower odds of all-cause mortality, cardiovascular mortality, cancer mortality, depression, osteoarthritis, COPD, and asthma — and positively associated with bone mineral density.⁶ A separate large NHANES analysis found that for every 20-percentile increase in appendicular skeletal muscle index, all-cause mortality risk dropped by approximately 14% (HR 0.86) and cancer mortality by 13% (HR 0.87).⁷

A dose-response meta-analysis of prospective cohort studies in middle-aged and older adults reported that low appendicular lean mass was associated with a 22% higher risk of all-cause mortality (RR 1.22, 95% CI 1.02–1.46).⁸

And in the São Paulo Ageing & Health Study, men with low ALM had an 11-fold higher adjusted odds of all-cause mortality over four years of follow-up — a stronger signal than visceral adipose tissue in the same model.⁹

You can be a "normal" BMI and still be dangerously under-muscled. This phenomenon — sarcopenic obesity — is invisible on a bathroom scale and invisible on a calculator. It only shows up on a DEXA scan, and ALMI is the line item that flags it.

The Research-Backed ALMI Cutoffs You Should Know

Three major international consensus groups publish ALMI/ALM cutoffs. Knowing which one applies to you depends on your age and population.

EWGSOP2 (European Working Group on Sarcopenia in Older People, 2019)

Confirmed sarcopenia requires both low strength and low muscle quantity. The muscle-mass criterion uses ALMI:

These thresholds are the most widely cited globally and are the ones used in the majority of European clinical research.¹¹⁰

FNIH Sarcopenia Project (Foundation for the National Institutes of Health, 2014)

The FNIH project pooled data from 26,625 participants across nine cohort studies and derived data-driven cutpoints tied to functional weakness rather than a young-adult reference population. FNIH recommends adjusting ALM for BMI rather than height:

The BMI-adjusted version is generally considered superior in higher-BMI populations because raw ALMI can look falsely reassuring at high body weight.²¹¹

AWGS 2019 (Asian Working Group for Sarcopenia)

AWGS uses DXA-derived ALMI cutoffs adapted to Asian body composition:

AWGS 2019 also explicitly endorses the FNIH BMI-adjusted criteria as an acceptable alternative when DXA is used.³

Important caveat: cutoffs are screening tools, not finish lines

These thresholds were designed to flag older adults at clinical risk. If you are a healthy 35-year-old strength training three times a week, you should be sitting well above these numbers — not next to them. Treat the cutoff as the floor of "danger zone," not the goal. The goal for healthy aging is to build a generous reserve in young adulthood and middle age so that the inevitable 1–2% annual loss of muscle after age 50 still leaves you well clear of frailty thresholds at age 75.⁸

Get your baseline ALMI with a DEXASCAN.com whole-body scan →

Why ALMI Matters More Than Ever in the GLP-1 Era

The fastest-growing reason to track ALMI in 2026 has nothing to do with aging. It has to do with GLP-1 and dual incretin medications — semaglutide, tirzepatide, and the next wave behind them.

These drugs work. They also drive substantial weight loss in a short period, and any rapid weight loss — whether from caloric restriction, surgery, or pharmacotherapy — is accompanied by loss of lean body mass alongside fat. Recent mechanistic work in Cell Reports Medicine confirmed that GLP-1 receptor agonists produce a preferential reduction of fat over lean body mass, but lean mass loss is not zero, and ALMI is the cleanest way to measure whether yours is staying intact.¹²

The clinical response to this concern is converging on three pillars:

1. High-protein intake (typically 1.2–1.6 g/kg of body weight per day during active weight loss)
2. Resistance training, started at the same time as the medication, not after weight is lost
3. Periodic body composition monitoring to verify that fat loss — not muscle loss — is what is actually happening

Mass General Brigham's recent grand rounds on GLP-1 and body composition made the point bluntly: weight loss without lean mass monitoring is flying blind, and combining the medication with both resistance training and high-protein intake produces the best preservation of muscle and bone.¹³ The American Diabetes Association's 2025 scientific sessions featured an entire late-breaking symposium on muscle-preserving combination therapies for GLP-1 users.¹⁴

If you are on a GLP-1, the scale is not the metric. Your ALMI trajectory is the metric. A drop of even 0.3–0.5 kg/m² in ALMI over a few months of GLP-1 therapy is a signal to immediately tighten protein, add or intensify resistance work, and rescan in 8–12 weeks. You cannot see this on a scale. You can see it clearly on a DEXA report.

How to Improve Your ALMI: What the Evidence Actually Supports

The interventions that move ALMI are unglamorous and well-established:

1. Progressive resistance training, 2–4 sessions per week

The single most powerful intervention. Sustained resistance training preserves ALMI across the lifespan and lowers the prevalence of sarcopenic obesity at every decade studied.

2. Adequate protein intake

For healthy adults, 1.0–1.2 g/kg/day is a maintenance floor. For adults in caloric deficit, on GLP-1 medications, or over age 65, the working target shifts to 1.2–1.6 g/kg/day, distributed across 3–4 meals to maximize per-meal muscle protein synthesis.

3. Avoid extended sedentary or immobilization periods

Even short bouts of bed rest or limb immobilization produce measurable ALM loss. The post-illness, post-surgery, and post-injury windows are where many adults silently lose years of ALMI reserve.

4. Track on the same machine, on the same protocol

GE Lunar and Hologic DXA systems produce systematically different absolute values for lean mass. To track trend reliably, you want repeat scans on the same machine, in the same hydration state, at a similar time of day. 

Book a follow-up DEXA scan to track your ALMI trend →

Why a Whole-Body DEXA Scan Is the Right Place to Measure ALMI

A whole-body DEXA scan from DEXASCAN.com gives you four metrics that no other single test produces together:

• ALMI and total lean mass (limb-by-limb)
• Visceral adipose tissue (VAT) — the metabolically dangerous abdominal fat
• Bone mineral density — your osteoporosis baseline
• Regional fat and lean balance — left vs. right, upper vs. lower

The whole scan takes about 7–10 minutes. Radiation exposure is roughly equivalent to a few hours of background radiation — orders of magnitude below CT. And because DEXASCAN.com operates a national network of approximately 300 certified clinics, you can scan, move, travel, and still re-test on equivalent equipment when you are ready to verify whether your training, your nutrition, or your GLP-1 protocol is doing what you think it is doing.

Track Your ALMI Trend in the DEXA Scan App

Getting a single ALMI number is useful. Tracking your ALMI trend over months and years is where the real value lives. Sarcopenia and sarcopenic obesity develop slowly. The earliest warning sign is not a low number — it is a downward trend in a number that used to be higher.

The free DEXA Scan app — available on iOS and Android — lets you:

• Store your full DEXA scan history in one place
• Visualize your ALMI, VAT, and body fat % trends over time
• Compare your numbers to age- and sex-matched reference ranges
• Set training and protein targets based on your actual body composition data
• Book your next scan at any DEXASCAN.com network clinic

Download the DEXA Scan app →

Frequently Asked Questions About ALMI

What is a good ALMI score for a healthy adult?

For young, healthy adults, mean ALMI is roughly 8.6 kg/m² for men and 6.1 kg/m² for women, based on recent  DEXA reference data.⁴ Sarcopenia thresholds (7.0 kg/m² for men, 5.5 kg/m² for women per EWGSOP2) are screening floors, not goals. Active, strength-training adults typically sit well above young-adult averages.

What is the difference between ALMI and ALM?

ALM is the raw kilograms of lean mass in your arms and legs combined. ALMI divides that number by your height squared to allow comparison across people of different sizes.

Is ALMI the same as FFMI?

No. FFMI includes all fat-free mass — limbs, trunk, organs, and bone. ALMI isolates only the lean tissue in your arms and legs, which is the most clinically meaningful measure of functional muscle.

Can I calculate ALMI from a smart scale or BIA device?

Not reliably. Bioelectrical impedance analysis estimates lean mass using equations and is highly sensitive to hydration, food intake, and device-specific algorithms. Validation studies show large device-to-device discrepancies in estimated ALM compared to DEXA.³ For clinical decisions, DEXA is the standard.

How often should I get a DEXA scan to track my ALMI?

For most adults, every 3-6 months is appropriate. For active interventions — starting a GLP-1, beginning a structured resistance training program, recovering from surgery or illness — 3–4 months is reasonable to detect early trends.

Is ALMI relevant for younger athletes, or only for older adults?

Both. The clinical thresholds were derived in older populations, but ALMI is an excellent training and recomposition metric at any age. Tracking ALMI lets you see whether your "muscle gain" phase is actually building appendicular muscle — or whether the scale weight is coming from somewhere else.

---

The Bottom Line

ALMI is the most evidence-backed muscle metric in clinical medicine. It is the one number on a DEXA scan that has been repeatedly tied to falls, fractures, disability, disease, and mortality across populations spanning North America, Europe, and Asia. If you have a DEXA scan, you have an ALMI value. Read it, write it down, and track it.

If you do not have a DEXA scan yet, the next step is simple.

Find a DEXASCAN.com clinic near you and book your whole-body scan →

Download the DEXA Scan app to track your ALMI trend →

---

References

---

Medical disclaimer: This article is for educational purposes and does not constitute medical advice. Sarcopenia diagnosis requires evaluation by a qualified clinician and typically involves measurement of both muscle mass and muscle strength or physical performance. DEXASCAN.com clinics provide body composition measurement; clinical interpretation should be conducted in partnership with your physician.

Footnotes

1. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019;48(1):16–31. doi:10.1093/ageing/afy169. Available at: https://academic.oup.com/ageing/article-abstract/48/1/16/5126243 ↩ ↩² ↩³

2. Studenski SA, Peters KW, Alley DE, et al. The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates. The Journals of Gerontology: Series A. 2014;69(5):547–558. doi:10.1093/gerona/glu010. Available at: https://academic.oup.com/biomedgerontology/article/69/5/547/672497 ↩ ↩²

3. Yamada M, Kimura Y, Ishiyama D, et al. Validating muscle mass cutoffs of four international sarcopenia-working groups in Japanese people using DXA and BIA. Journal of Cachexia, Sarcopenia and Muscle. 2021;12(4):1000–1010. doi:10.1002/jcsm.12732. Available at: https://onlinelibrary.wiley.com/doi/full/10.1002/jcsm.12732 ↩ ↩² ↩³ ↩⁴

4. Cut-off values for the muscle mass indices determined using DXA in healthy Polish adults — a comparison to EWGSOP2 recommendation. Aging. 2025. Available at: https://www.aging-us.com/article/206206/text ↩ ↩²

5. Which is the best alternative to estimate muscle mass for sarcopenia diagnosis when DXA is unavailable? Archives of Gerontology and Geriatrics. 2021. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0167494321001801 ↩

6. Comprehensive evaluation of appendicular lean mass and sarcopenia on human health: evidence from the NHANES program. Archives of Gerontology and Geriatrics. 2026. Available at: https://www.sciencedirect.com/science/article/pii/S0531556526000276 ↩

7, Low appendicular skeletal muscle mass is associated with the risk of mortality among adults in the United States. Scientific Reports. 2025. Available at: https://www.nature.com/articles/s41598-025-94357-8 ↩

8, Low lean mass and all-cause mortality risk in the middle-aged and older population: a dose-response meta-analysis of prospective cohort studies. PMC. 2025. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12237975/ ↩ ↩²

9. Association of Appendicular Lean Mass, and Subcutaneous and Visceral Adipose Tissue With Mortality in Older Brazilians: The São Paulo Ageing & Health Study. Journal of Clinical Endocrinology & Metabolism. 2019. Available at: https://pubmed.ncbi.nlm.nih.gov/30866105/ ↩

10. Recent sarcopenia definitions — prevalence, agreement and mortality associations among men: Findings from population-based cohorts. Journal of Cachexia, Sarcopenia and Muscle. 2023. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891989/ ↩

11. Batsis JA, Mackenzie TA, Lopez-Jimenez F, Bartels SJ. Sarcopenia, Sarcopenic Obesity and Functional Impairments in Older Adults: NHANES 1999–2004. Clinical Nutrition. 2016. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4825802/ ↩

12. Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans. Cell Reports Medicine. 2026. Available at: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00082-0 ↩

13. Preserving Lean Body Mass in Patients Taking GLP-1 for Weight Loss. Mass General Brigham Advances in Motion. 2025. Available at: https://advances.massgeneral.org/endocrinology/article.aspx?id=1601 ↩

14. New GLP-1 Therapies Enhance Quality of Weight Loss by Improving Muscle Preservation. American Diabetes Association. 2025. Available at: https://diabetes.org/newsroom/press-releases/new-glp-1-therapies-enhance-quality-weight-loss-improving-muscle-0 ↩